Marinus Pharma (MRNS) Announces Elan Ezickson to Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Pre-Open Movers 12/11: (PTI) (OLLI) (PLAB) Higher (ITRM) (GME) (PLCE) Lower (more...)
December 11, 2019 9:19 AM ESTToday's Pre-Open Movers
Iterum Therapeutics plc (Nasdaq: ITRM) 46.2% LOWER; announced topline results from its Sulopenem for Resistant Enterobacteriaceae (SURE) 3 clinical trial in complicated intra-abdominal infections (cIAI). The primary U.S. Food and Drug Administration (FDA) endpoint was clinical response on Day 28 in the micro-MITT population. In this population, the difference in outcomes was 4.7% with a 95% confidence interval on that difference of -10.3% to 1.0%. Non-inferiority required that the lower limit of the difference in the outcome rates be >-10% for FDA.
Marinus Pharma (MRNS) Prices 28M Share Common Offering at $1.25/Sh; Announces Concurrent Private Placement
December 11, 2019 9:15 AM ESTMarinus Pharmaceuticals, Inc. (NASDAQ: MRNS) today announced the pricing of an underwritten public offering of 28,000,000 shares of common stock at a public offering price of $1.25 per share. The gross proceeds to the Company from the public offering and concurrent private placement are expected to be approximately $65 million before deducting underwriting discounts and commissions, placement agent fees, and other estimated offering expenses. The Company has granted to the underwriters... More
After-Hours Movers 12/10: (ASPU) (OLLI) (PLAY) Higher; (ITRM) (GME) (AQST) Lower (more...)
December 10, 2019 5:28 PM ESTToday's After-Hours Movers
Iterum Therapeutics plc (Nasdaq: ITRM) 38.6% LOWER; announced topline results from its Sulopenem for Resistant Enterobacteriaceae (SURE) 3 clinical trial in complicated intra-abdominal infections (cIAI). The primary U.S. Food and Drug Administration (FDA) endpoint was clinical response on Day 28 in the micro-MITT population. In this population, the difference in outcomes was 4.7% with a 95% confidence interval on that difference of -10.3% to 1.0%. Non-inferiority required that the lower limit of the difference in the outcome rates be >-10% for FDA.
GameStop (NYSE:... More
Marinus Pharma (MRNS) Plans Public Offering of Common Stock and Concurrent Private Placement
December 10, 2019 4:26 PM ESTMarinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (Marinus or the Company) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the offering are to be sold by Marinus. Marinus also expects to grant the underwriters a 30-day option to purchase up to an... More
